160 related articles for article (PubMed ID: 20146481)
1. Toward biophysical probes for the 5-HT3 receptor: structure-activity relationship study of granisetron derivatives.
Vernekar SK; Hallaq HY; Clarkson G; Thompson AJ; Silvestri L; Lummis SC; Lochner M
J Med Chem; 2010 Mar; 53(5):2324-8. PubMed ID: 20146481
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of photoaffinity probes that target the 5-HT3 receptor.
Jack T; Ruepp MD; Thompson AJ; Mühlemann O; Lochner M
Chimia (Aarau); 2014; 68(4):239-42. PubMed ID: 24983606
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Pharmacological Evaluation of [
Mu L; Müller Herde A; Rüefli PM; Sladojevich F; Milicevic Sephton S; Krämer SD; Thompson AJ; Schibli R; Ametamey SM; Lochner M
ACS Chem Neurosci; 2016 Nov; 7(11):1552-1564. PubMed ID: 27571447
[TBL] [Abstract][Full Text] [Related]
4. The binding orientations of structurally-related ligands can differ; A cautionary note.
Ruepp MD; Wei H; Leuenberger M; Lochner M; Thompson AJ
Neuropharmacology; 2017 Jun; 119():48-61. PubMed ID: 28137449
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Orthosteric Binding Site of the Human 5-HT
Jack T; Leuenberger M; Ruepp MD; Vernekar SKV; Thompson AJ; Braga-Lagache S; Heller M; Lochner M
ACS Chem Neurosci; 2019 Jan; 10(1):438-450. PubMed ID: 30149702
[TBL] [Abstract][Full Text] [Related]
6. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
7. Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.
Steward LJ; Ge J; Bentley KR; Barber PC; Hope AG; Lambert JJ; Peters JA; Blackburn TP; Barnes NM
Br J Pharmacol; 1995 Sep; 116(2):1781-8. PubMed ID: 8528560
[TBL] [Abstract][Full Text] [Related]
8. Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.
Thompson AJ; Chau PL; Chan SL; Lummis SC
Biophys J; 2006 Mar; 90(6):1979-91. PubMed ID: 16387779
[TBL] [Abstract][Full Text] [Related]
9. Development of potent serotonin-3 (5-HT3) receptor antagonists. II. Structrue-activity relationships of N-(1-benzyl-4-methylhexahydro-1H-1,4- diazepin-6-yl)carboxamides.
Harada H; Morie T; Hirokawa Y; Terauchi H; Fujiwara I; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1912-30. PubMed ID: 8575032
[TBL] [Abstract][Full Text] [Related]
10. Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets.
Endo T; Ogawa T; Hamaue N; Akita K; Hirafuji M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Jun; 100(3):243-53. PubMed ID: 9730004
[TBL] [Abstract][Full Text] [Related]
11. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
Heidempergher F; Pillan A; Pinciroli V; Vaghi F; Arrigoni C; Bolis G; Caccia C; Dho L; McArthur R; Varasi M
J Med Chem; 1997 Oct; 40(21):3369-80. PubMed ID: 9341912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the 5-HT1A, 5-HT2 and 5-HT3 receptors in the bovine ciliary muscle.
Lograno MD; Romano MR
Eur J Pharmacol; 2003 Mar; 464(1):69-74. PubMed ID: 12600697
[TBL] [Abstract][Full Text] [Related]
13. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
Hargreaves AC; Gunthorpe MJ; Taylor CW; Lummis SC
Mol Pharmacol; 1996 Nov; 50(5):1284-94. PubMed ID: 8913360
[TBL] [Abstract][Full Text] [Related]
14. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
Orjales A; Mosquera R; Labeaga L; Rodes R
J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological characterization of a new benzoxazole derivative as a potent 5-HT3 receptor agonist.
López-Tudanca PL; Labeaga L; Innerárity A; Alonso-Cires L; Tapia I; Mosquera R; Orjales A
Bioorg Med Chem; 2003 Jul; 11(13):2709-14. PubMed ID: 12788344
[TBL] [Abstract][Full Text] [Related]
16. Ondansetron and granisetron binding orientation in the 5-HT(3) receptor determined by unnatural amino acid mutagenesis.
Duffy NH; Lester HA; Dougherty DA
ACS Chem Biol; 2012 Oct; 7(10):1738-45. PubMed ID: 22873819
[TBL] [Abstract][Full Text] [Related]
17. Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands.
Barnes JM; Barnes NM; Costall B; Jagger SM; Naylor RJ; Robertson DW; Roe SY
Br J Pharmacol; 1992 Feb; 105(2):500-4. PubMed ID: 1559139
[TBL] [Abstract][Full Text] [Related]
18. The interactions of the 5-HT3 receptor with quipazine-like arylpiperazine ligands: the journey track at the end of the first decade of the third millennium.
Cappelli A; Butini S; Brizzi A; Gemma S; Valenti S; Giuliani G; Anzini M; Mennuni L; Campiani G; Brizzi V; Vomero S
Curr Top Med Chem; 2010; 10(5):504-26. PubMed ID: 20166948
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of ligand recognition in 5-HT3 receptors.
Kesters D; Thompson AJ; Brams M; van Elk R; Spurny R; Geitmann M; Villalgordo JM; Guskov A; Danielson UH; Lummis SC; Smit AB; Ulens C
EMBO Rep; 2013 Jan; 14(1):49-56. PubMed ID: 23196367
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
